GSK (GSK) said Friday that Health Canada approved a prefilled syringe presentation of its shingles vaccine, Shingrix, eliminating the need to reconstitute separate vials before administration.
The company said the approval was based on data demonstrating technical comparability between the new prefilled syringe and the existing presentation.
GSK said it expects the new format to become available in Canada in early 2027.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.